Start-Up Previews (12/04)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Artificial Blood, features profiles of Haemostatix, Hemobiotech, Hemocellular Therapeutics and Sangart. Plus these Start-Ups across Health Care: Gloucester Pharmaceuticals, HistoRx, Symphony Medical and Yaupon Therapeutics.
You may also be interested in...
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.
In a pair of guidance documents the US agency explains clearance options and its enforcement policy for sponsors of devices used to reduce contaminants in COVID-19 masks and respirators.
Medical and advocacy groups claim FDA is requiring women to fill prescriptions for Mifeprex in person while waiving REMS requirement for in-person visits for other drugs.